^
    Apply
    A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations (NCT05588141)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/16/2023
    Primary completion :
    08/01/2025
    Completion :
    08/02/2029
    IDH1 • IDH2
    |
    IDH2 mutation
    |
    zotiraciclib (TG02)
    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (NCT03922724)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/18/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2029
    ALK • HLA-B • HLA-C
    |
    ALK positive
    |
    Jakafi (ruxolitinib) • cyclophosphamide • sirolimus
    Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY007) (NCT02713386)
    Phase 1/2
    NRG Oncology
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/14/2016
    Primary completion :
    09/30/2021
    Completion :
    08/01/2025
    BRCA1 • BRCA2 • BRCA • CRP
    |
    carboplatin • paclitaxel • Jakafi (ruxolitinib)
    Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) (NCT06052618)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    01/01/2033
    Completion :
    01/01/2034
    CRP
    |
    Vonjo (pacritinib)
    Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors (NCT03610971)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    11/19/2019
    Primary completion :
    02/01/2025
    Completion :
    02/01/2026
    ABL1 • BCR
    |
    Jakafi (ruxolitinib)
    A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER) (NCT05936359)
    Phase 1
    Incyte Corporation
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    09/25/2023
    Primary completion :
    02/29/2028
    Completion :
    02/29/2028
    CALR
    |
    Jakafi (ruxolitinib)
    Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) (MCC-20963) (NCT05177211)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/01/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    ABL1 • BCR
    |
    Inrebic (fedratinib)
    A Study of Ruxolitinib and Duvelisib in People With Lymphoma (NCT05010005)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    08/12/2021
    Primary completion :
    08/01/2026
    Completion :
    08/01/2026
    CD8
    |
    CD8 positive
    |
    Jakafi (ruxolitinib) • Copiktra (duvelisib)
    Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis (SENTRY) (NCT04562389)
    Phase 3
    Karyopharm Therapeutics Inc
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    03/11/2021
    Primary completion :
    09/01/2025
    Completion :
    03/01/2028
    CD4
    |
    Jakafi (ruxolitinib) • Xpovio (selinexor)
    Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation (MPN-RC 119) (NCT04281498)
    Phase 2
    John Mascarenhas
    Completed
    Last update posted :
    02/04/2025
    Initiation :
    01/14/2021
    Primary completion :
    05/30/2023
    Completion :
    05/30/2023
    IDH2
    |
    IDH2 mutation
    |
    Jakafi (ruxolitinib) • Idhifa (enasidenib)
    Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma (NCT05440942)
    Phase 1
    Peter Hosein, MD
    Active, not recruiting
    Last update posted :
    09/11/2024
    Initiation :
    01/19/2023
    Primary completion :
    03/01/2025
    Completion :
    09/01/2027
    TMB • BRCA1 • BRCA2 • MSI
    |
    MSI-H/dMMR
    |
    Mekinist (trametinib) • Jakafi (ruxolitinib) • Zynyz (retifanlimab-dlwr)
    Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older (NCT02494882)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    07/29/2024
    Initiation :
    06/29/2015
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP
    |
    BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R
    |
    dasatinib • Jakafi (ruxolitinib) • dexamethasone
    Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) (NCT04551495)
    Phase 2
    Jules Bordet Institute
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    01/14/2021
    Primary completion :
    08/01/2024
    Completion :
    10/01/2024
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    Rozlytrek (entrectinib) • letrozole • goserelin acetate
    Ruxolitinib in Estrogen Receptor Positive Breast Cancer (UPCC 02112) (NCT01594216)
    Phase 2
    Abramson Cancer Center at Penn Medicine
    Completed
    Last update posted :
    06/12/2024
    Initiation :
    04/01/2012
    Primary completion :
    04/01/2016
    Completion :
    04/09/2016
    ER
    |
    Jakafi (ruxolitinib) • exemestane
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (NCT05170204)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    11/01/2022
    Primary completion :
    06/17/2029
    Completion :
    04/14/2035
    PD-L1 • RET • ROS1
    |
    RET fusion • ALK fusion • ROS1 fusion
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Gavreto (pralsetinib)
    Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia (NCT02257138)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/08/2024
    Initiation :
    02/12/2015
    Primary completion :
    03/19/2021
    Completion :
    03/19/2021
    JAK2
    |
    JAK2 mutation
    |
    azacitidine • Jakafi (ruxolitinib) • decitabine
    JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure (NCT05998408)
    Phase 1/2
    National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    02/20/2024
    Primary completion :
    06/03/2030
    Completion :
    06/03/2032
    CD8 • B3GAT1
    |
    Jakafi (ruxolitinib)
    Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer (NCT02876302)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    04/18/2024
    Initiation :
    01/24/2018
    Primary completion :
    12/31/2022
    Completion :
    08/01/2024
    HER-2 • PGR
    |
    HER-2 negative
    |
    paclitaxel • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • cyclophosphamide intravenous
    Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) (NCT02650401)
    Phase 1/2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    03/29/2024
    Initiation :
    05/03/2016
    Primary completion :
    06/15/2025
    Completion :
    06/15/2025
    ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion
    |
    Rozlytrek (entrectinib)
    Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) (NCT02568267)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    03/28/2024
    Initiation :
    11/19/2015
    Primary completion :
    12/31/2024
    Completion :
    04/01/2025
    ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    ALK rearrangement • ROS1 rearrangement
    |
    Xalkori (crizotinib) • Rozlytrek (entrectinib)
    A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression (NCT02891603)
    Phase 1/2
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    03/25/2024
    Initiation :
    06/08/2017
    Primary completion :
    01/28/2022
    Completion :
    04/18/2022
    IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C
    |
    sirolimus • Vonjo (pacritinib)
    Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis (ALLO-BAT) (NCT04217356)
    Phase N/A
    University Health Network, Toronto
    Recruiting
    Last update posted :
    03/22/2024
    Initiation :
    08/05/2020
    Primary completion :
    08/05/2025
    Completion :
    02/05/2026
    TP53 • IDH1 • IDH2 • JAK2 • ASXL1 • SRSF2 • U2AF1 • CALR
    |
    TP53 mutation • ASXL1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation • CALR mutation
    |
    Jakafi (ruxolitinib) • hydroxyurea
    A Study of LY2784544 in Participants With Myeloproliferative Neoplasms (NCT01594723)
    Phase 2
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    03/21/2024
    Initiation :
    05/22/2012
    Primary completion :
    03/20/2015
    Completion :
    12/01/2024
    JAK2
    |
    JAK2 V617F • JAK2 mutation
    |
    gandotinib (LY 2784544)
    Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia (NCT05396859)
    Phase 1
    OHSU Knight Cancer Institute
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    10/28/2022
    Primary completion :
    12/31/2024
    Completion :
    06/30/2025
    TP53 • RUNX1 • MAPK1 • NTRK • MAPK3
    |
    TP53 mutation • NTRK expression
    |
    Rozlytrek (entrectinib) • Inqovi (decitabine/cedazuridine)
    Ruxolitinib in Thrombocythemia and Polycythemia Vera (NCT04644211)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    03/08/2024
    Initiation :
    03/21/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    JAK2
    |
    JAK2 mutation
    |
    Jakafi (ruxolitinib)
    Ruxolitinib + Allogeneic Stem Cell Transplantation in AML (NCT03286530)
    Phase 2
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    03/07/2024
    Initiation :
    11/03/2017
    Primary completion :
    12/01/2024
    Completion :
    12/01/2026
    HLA-B
    |
    Jakafi (ruxolitinib)
    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (NCT05088356)
    Phase 1
    Stanford University
    Recruiting
    Last update posted :
    02/19/2024
    Initiation :
    09/07/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HLA-DRB1 • HLA-B • HLA-C
    |
    Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor
    DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. (NCT05770544)
    Phase 2/3
    Cancer Research UK
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    06/01/2024
    Primary completion :
    10/01/2029
    Completion :
    10/01/2029
    ROS1
    |
    ROS1 fusion • ROS1 positive
    |
    Rozlytrek (entrectinib)
    Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia (NCI-2022-02385) (NCT05592015)
    Phase 2
    John Reneau
    Recruiting
    Last update posted :
    01/31/2024
    Initiation :
    05/03/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    CD8 • STAT3 • B3GAT1
    |
    STAT3 mutation
    |
    Jakafi (ruxolitinib)
    Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer (NCT03012230)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    01/31/2024
    Initiation :
    12/06/2017
    Primary completion :
    01/06/2023
    Completion :
    03/08/2023
    HER-2 • PD-L1 • ER • PGR • JAK2 • PD-L2
    |
    PD-L1 expression • PD-L1 amplification • PGR expression
    |
    Keytruda (pembrolizumab) • Jakafi (ruxolitinib)
    A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (AALL1521) (NCT02723994)
    Phase 2
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    01/12/2024
    Initiation :
    09/30/2016
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    JAK2 • CRLF2 • JAK1 • IL7R • EPOR • SH2B3
    |
    CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 fusion • SH2B3 deletion
    |
    cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Erwinase (erwinia asparaginase)
    Tofacitinib in Recurrent GBM Patients (NCT05326464)
    Phase 3
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    01/09/2024
    Initiation :
    10/07/2022
    Primary completion :
    06/01/2024
    Completion :
    06/01/2026
    EGFR • MGMT
    |
    EGFR amplification • IDH wild-type
    |
    tofacitinib
    Neratinib in Combination With Ruxolitinib in Patients With mTNBC (NCT06008275)
    Phase 1
    Baylor Research Institute
    Not yet recruiting
    Last update posted :
    11/30/2023
    Initiation :
    11/01/2023
    Primary completion :
    06/01/2025
    Completion :
    12/01/2025
    ER
    |
    ER negative
    |
    Nerlynx (neratinib) • Jakafi (ruxolitinib)
    Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (NCT01895842)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    11/29/2023
    Initiation :
    02/01/2014
    Primary completion :
    04/02/2019
    Completion :
    04/02/2019
    JAK2 • NFKB1
    |
    JAK2 mutation
    |
    Jakafi (ruxolitinib)
    Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia (NCT03571321)
    Phase 1
    University of Chicago
    Recruiting
    Last update posted :
    11/29/2023
    Initiation :
    05/28/2019
    Primary completion :
    09/01/2026
    Completion :
    09/05/2027
    JAK2 • CRLF2 • IL7R • SH2B3
    |
    CRLF2 rearrangement • JAK2 mutation • IL7R mutation • JAK2 rearrangement • SH2B3 deletion
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • cyclophosphamide intravenous
    Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia (NCT03654768)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    11/13/2023
    Initiation :
    10/24/2018
    Primary completion :
    07/01/2024
    Completion :
    07/01/2028
    ABL1 • BCR
    |
    dasatinib • imatinib • Jakafi (ruxolitinib) • Tasigna (nilotinib) • Bosulif (bosutinib)
    Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders (NCT03801434)
    Phase 2
    William Shomali
    Recruiting
    Last update posted :
    11/02/2023
    Initiation :
    11/15/2019
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    JAK2 • ETV6 • PCM1
    |
    JAK2 mutation • JAK2 rearrangement
    |
    Jakafi (ruxolitinib)
    Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma (NCT04303403)
    Phase 1
    National Cancer Centre, Singapore
    Recruiting
    Last update posted :
    10/11/2023
    Initiation :
    07/31/2018
    Primary completion :
    06/30/2023
    Completion :
    03/31/2024
    KRAS
    |
    KRAS mutation • RAS mutation
    |
    Mekinist (trametinib) • Jakafi (ruxolitinib)
    Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection (NCT05713279)
    Phase N/A
    Chengdu Zenitar Biomedical Technology Co., Ltd
    Active, not recruiting
    Last update posted :
    09/26/2023
    Initiation :
    01/19/2023
    Primary completion :
    11/01/2023
    Completion :
    11/30/2023
    IL6
    |
    flonoltinib
    De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis (NCT05622318)
    Phase 2
    Medical College of Wisconsin
    Recruiting
    Last update posted :
    08/31/2023
    Initiation :
    08/29/2023
    Primary completion :
    12/15/2025
    Completion :
    12/15/2025
    HLA-DRB1 • HLA-B • HLA-C
    |
    Jakafi (ruxolitinib) • cyclophosphamide